Moderna

MRNA

mRNA technology platform pioneer. Beyond COVID vaccines, developing personalized cancer vaccines, rare disease treatments, and respiratory therapeutics.

FDA ApprovedBreakthrough Device

$35.20

-2.5%

Market Data

Headquarters

Cambridge, MA

CEO

Stephane Bancel

Founded

2010

Employees

5,800+

Sector

mRNA Therapeutics

Therapeutic Area

Oncology, Infectious Disease, Rare Disease

Stage

Public

Total Funding

Public (NASDAQ: MRNA)

Regulatory Pipeline

mRNA-4157 Cancer Vaccine

PMA · Class III · Feb 2024

Breakthrough

Funding History

Series A

2012

$40M

Flagship Pioneering

IPO

2018-12-07

$621M

NASDAQ

Clinical Trials

KEYNOTE-942 Melanoma

Recruiting

Phase III · Global

mRNA-1283 NextGen COVID

Completed

Phase III · US, EU

Open Positions

LNP Process Engineer

Manufacturing · Norwood, MA

$130K-$170K+ RSUs

LNPmRNAGMP

← Back to Directory